Gut Microbiota and Amino Acid Metabolism in Post-CPB Delayed Neurocognitive Recovery
Role of the Holdemanella Biformis-Related Amino Acid Metabolic Guild and Intestinal Barrier Injury in Cardiopulmonary Bypass-Associated Delayed Neurocognitive Recovery: A Prospective Observational Cohort Study
Delayed neurocognitive recovery (dNCR) is a common neurological complication in adult patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). Emerging evidence suggests that CPB-associated hypoperfusion and perioperative stress remodel the gut microbiome and impair intestinal barrier integrity, which may contribute to neuroinflammation and cognitive decline via the gut-brain axis. This prospective observational cohort study aims to investigate the longitudinal trajectories of the gut metagenome (specifically focusing on Holdemanella biformis and amino acid metabolic functions), fecal and plasma metabolites (L-lysine, L-tryptophan, tryptophanol, and short-chain fatty acids), and plasma markers of intestinal barrier injury (I-FABP) and endotoxin response (LBP) from pre-operation (T0) to post-operation (T2) in adult CPB patients, and to evaluate their associations with postoperative dNCR and domain-specific cognitive changes.
調査の概要
状態
詳細な説明
Adult patients (aged 18 years or older) scheduled for elective cardiac surgery under cardiopulmonary bypass (CPB) will be prospectively enrolled. Comprehensive neuropsychological assessments covering global cognition (MoCA), learning and memory (HVLT or RAVLT), executive function (Trail Making Test B), and attention/processing speed (Digit Span and Digit Symbol tests) will be conducted at baseline (T0: 1 to 3 days before surgery) and postoperatively (T2: 5 to 10 days after surgery or before hospital discharge). Postoperative delirium will be screened daily using CAM or CAM-ICU. Paired stool and blood samples will be collected at both T0 and T2. Stool samples will undergo shotgun metagenomic sequencing and targeted metabolomics profiling (pre-specified panel: L-lysine, L-tryptophan, tryptophanol, acetate, propionate, and butyrate). Blood samples will be analyzed for intestinal fatty acid-binding protein (I-FABP) and lipopolysaccharide-binding protein (LBP). Linear mixed-effects models and multivariable regression adjusting for age and clinical covariates will be applied to identify time-by-dNCR interaction effects and associations with the continuous global cognitive composite delta-Z score.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前：Xiaoliang Wang
- 電話番号：13776615743
- メール：wxl145381@njmu.edu.cn
研究連絡先のバックアップ
- 名前：Feier Chen
- 電話番号：18155529314
- メール：Liberate0109@outlook.com
研究場所
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210006
- 募集
- Nanjing First Hospital
-
コンタクト：
- Xiaoliang Wang
- 電話番号：13776615743
- メール：wxl145381@njmu.edu.cn
-
コンタクト：
- Feier Chen
- 電話番号：18155529314
- メール：Liberate0109@outlook.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Adult patients (aged 18 years or older) admitted to Nanjing First Hospital for elective cardiac surgery requiring cardiopulmonary bypass (CPB).
説明
Inclusion Criteria:
- (1) Aged 18 years or older; (2) Scheduled for elective cardiac surgery under cardiopulmonary bypass (CPB); (3) Able to complete Chinese neurocognitive assessments at baseline; (4) Able to provide a baseline stool sample at T0 (1 to 3 days before surgery); (5) Signed informed consent obtained.
Exclusion Criteria:
- (1) Preoperative delirium; (2) Inability to complete baseline neurocognitive assessments (e.g., severe visual, auditory, or language impairment); (3) Active gastrointestinal infection or inflammatory bowel disease (IBD); (4) History of recent fecal microbiota transplantation (FMT); (5) Severe pre-existing neurological or psychiatric disorders (e.g., dementia, stroke with severe sequelae, schizophrenia).
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 観測モデル：COHORT
- 時間の展望：PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Adult CPB Cohort
Adult patients aged 18 years or older undergoing elective cardiac surgery with cardiopulmonary bypass (CPB), evaluated longitudinally at T0 (1-3 days preoperatively) and T2 (5-10 days postoperatively or before discharge) for cognitive function, gut microbiome, fecal metabolites, and plasma intestinal injury biomarkers. |
Observational collection of paired stool and blood samples and administration of neuropsychological test batteries at T0 and T2 during routine perioperative care for cardiac surgery with CPB. No experimental therapeutic intervention is administered. |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Global Cognitive Composite Z-Score (Delta-Z)
時間枠：Baseline (T0: 1 to 3 days before surgery) and Postoperative (T2: 5 to 10 days after surgery or prior to hospital discharge)
|
A composite cognitive Z-score calculated from a neuropsychological test battery assessing learning and memory (Hopkins Verbal Learning Test [HVLT] or Rey Auditory Verbal Learning Test [RAVLT]), executive function (Trail Making Test Part B [TMT-B]), and attention/processing speed (Digit Span and Digit Symbol tests). Individual test change scores (T2 minus T0) are standardized and combined into a global cognitive composite delta-Z score (higher values indicate better cognitive preservation). |
Baseline (T0: 1 to 3 days before surgery) and Postoperative (T2: 5 to 10 days after surgery or prior to hospital discharge)
|
|
Incidence of Delayed Neurocognitive Recovery (dNCR)
時間枠：From baseline (T0: 1 to 3 days before surgery) to T2 (5 to 10 days after surgery or prior to hospital discharge)
|
Proportion of participants classified as having delayed neurocognitive recovery (dNCR) at T2 based on the reliable change index / pre-specified Z-score decline rules across the neuropsychological battery and Montreal Cognitive Assessment (MoCA). |
From baseline (T0: 1 to 3 days before surgery) to T2 (5 to 10 days after surgery or prior to hospital discharge)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Changes in Fecal Metagenomic Taxonomic and Functional Profiles
時間枠：Baseline (T0: 1 to 3 days before surgery) and Postoperative (T2: 5 to 10 days after surgery or prior to hospital discharge)
|
Longitudinal changes in gut microbial community structure, specifically the relative abundance, prevalence, and strain markers of Holdemanella biformis, and KEGG Orthology (KO)/MetaCyc functional modules related to lysine, tryptophan, phosphotransferase system (PTS), and short-chain fatty acid (SCFA) metabolism. |
Baseline (T0: 1 to 3 days before surgery) and Postoperative (T2: 5 to 10 days after surgery or prior to hospital discharge)
|
|
Changes in Fecal Targeted Amino Acid Metabolites and Short-Chain Fatty Acids (SCFAs)
時間枠：Baseline (T0: 1 to 3 days before surgery) and Postoperative (T2: 5 to 10 days after surgery or prior to hospital discharge)
|
Concentrations of pre-registered fecal metabolites including L-lysine, L-tryptophan, tryptophanol, acetate, propionate, and butyrate quantified at T0 and T2. |
Baseline (T0: 1 to 3 days before surgery) and Postoperative (T2: 5 to 10 days after surgery or prior to hospital discharge)
|
|
Changes in Plasma Intestinal Fatty Acid-Binding Protein (I-FABP) and Lipopolysaccharide-Binding Protein (LBP)
時間枠：Baseline (T0: 1 to 3 days before surgery) and Postoperative (T2: 5 to 10 days after surgery or prior to hospital discharge)
|
Blood levels of I-FABP (marker of intestinal epithelial injury) and LBP (marker of host endotoxin response) measured by ELISA. |
Baseline (T0: 1 to 3 days before surgery) and Postoperative (T2: 5 to 10 days after surgery or prior to hospital discharge)
|
|
Incidence of Postoperative Delirium (POD)
時間枠：Postoperative Day 1 through Postoperative Day 7 (or hospital discharge)
|
Assessed daily after surgery using the Confusion Assessment Method (CAM) or CAM for the Intensive Care Unit (CAM-ICU). |
Postoperative Day 1 through Postoperative Day 7 (or hospital discharge)
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター：Xiaoliang Wang、The First Affiliated Hospital with Nanjing Medical University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- KY20190404-03-KS-01
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。